Blaine Labs said Jan. 27 that the affected lot is BL 2844, with an expiration date of Feb. 19, 2023. It was distributed to 61 physician clinics across 17 states in 2021.
Patients who apply the contaminated product to a wound could develop a skin and soft tissue infection, which could lead to serious complications. For immunocompromised patients and premature infants, the bacteria can cause life-threatening infections including wound and blood infections, sepsis, pneumonia and meningitis.
Blaine Labs said it is arranging for the return of undispensed 1-ounce bottles and 3-ounce tubes from the recalled lot. Patients who have the RevitaDerm Wound Care Gel 1-ounce bottles or 3-ounce tubes should stop using the product and return it to their dispensing physician, the lab said.
The company said that to date, it has not received any complaints or reports of adverse events related to the recalled lot of RevitaDerm gel.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.